Future growth expectations in sales/revenue/volumes?

Revenue potential is estimated between Rs. 2,500 crores to Rs. 3,000 crores, likely over the next three years. Existing products are expected to grow at an industry rate of 5-6% annually. New product launches, including performance chemicals and HALS, will drive significant growth and absorb overheads. HALS sales target: from Rs. 80 crores in FY '25 to Rs. 210 crores in FY '26 and ramping up fully by FY '27-’28 with total capacity over 10,000 tons. Performance chemicals (two new products) to commercialize in FY '26; revenue contribution expected mostly from FY '27 onward. MEHQ volumes anticipa

Any current/future new fundraising through debt or equity?

There is no specific mention of any new fundraising through debt or equity in the transcript. The company has undertaken significant CAPEX totaling Rs. 300 crores for FY '25 and FY '26 focused on two new performance chemical products. For FY '27, CAPEX plans will be announced after the commercialization and ramp-up of these new products. No mention of debt or equity issuance was made during the call. The company maintains a strong cash balance of Rs. 400 crores despite increased CAPEX and higher dividend payout. The focus appears to be on internal cash generation and operational growth rather

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue potential is expected to be Rs. 2,500 to Rs. 3,000 crores within the next three years. EBITDA margins are targeted to be maintained around 40% at the consolidated level, driven by a mix of HALS, pharma intermediates, and performance chemicals. HALS segment revenue is projected to grow from Rs. 80 crores in FY ’25 to Rs. 210 crores in FY ’26, with a full ramp-up expected around FY ’27–’28. Industry-standard growth rates of 4%-5% are expected for products like MEHQ, TBHQ, and BHA. Operating profit growth at the consolidated level is anticipated to be in the range of 18%-20% in FY

Any current/future capex/capital investment/strategic investment?

FY ’25 CAPEX: Rs. 215 crores invested in subsidiary Clean Fino-Chem. FY ’26 CAPEX: Rs. 300 crores planned, primarily for two new performance chemical projects. - One product commercialization expected by August FY ’26. - Second product commercialization expected by February FY ’26. Further CAPEX plans for FY ’27 will be announced around six months after these products come online. No immediate CAPEX projects slated for FY ’27 as of now; future investments contingent on commercialization progress. HALS capacity expansion (total capacity over 10,000 tons) ramp-up expected by FY ’28 before co

IN US

Sale is live|00:00:00left today

Clean Science & Technology LtdQ1 FY25Chemicals & Petrochemicals

Clean Science & Technology Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹770P/E: 35.5Market Cap: ₹8.1K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Revenue potential is estimated between Rs. 2,500 crores to Rs. 3,000 crores, likely over the next three years.
→Existing products are expected to grow at an industry rate of 5-6% annually.
→New product launches, including performance chemicals and HALS, will drive significant growth and absorb overheads.
→HALS sales target: from Rs. 80 crores in FY '25 to Rs. 210 crores in FY '26 and ramping up fully by FY '27-’28 with total capacity over 10,000 tons.
→Performance chemicals (two new products) to commercialize in FY '26; revenue contribution expected mostly from FY '27 onward.
→MEHQ volumes anticipated to grow 4%-5% year-on-year.
→Domestic market share expansion possible, e.g., up to 65% in HALS segment.
→EBITDA margins targeted around 40% at consolidated level by FY '26-’27.

Margin guidance

Category 3

→Revenue potential is expected to be Rs. 2,500 to Rs. 3,000 crores within the next three years.
→EBITDA margins are targeted to be maintained around 40% at the consolidated level, driven by a mix of HALS, pharma intermediates, and performance chemicals.
→HALS segment revenue is projected to grow from Rs. 80 crores in FY ’25 to Rs. 210 crores in FY ’26, with a full ramp-up expected around FY ’27–’28.
→Industry-standard growth rates of 4%-5% are expected for products like MEHQ, TBHQ, and BHA.
→Operating profit growth at the consolidated level is anticipated to be in the range of 18%-20% in FY ’26, supported by volume growth and new product launches that will absorb overhead costs.
→New performance chemical products and pharma intermediates will provide margin accretive growth as they scale up.
→HALS volumes are expected to grow significantly from 600 tons in FY ’24 to 4,500 tons in FY ’26.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no specific mention of any new fundraising through debt or equity in the transcript.
→The company has undertaken significant CAPEX totaling Rs. 300 crores for FY '25 and FY '26 focused on two new performance chemical products.
→For FY '27, CAPEX plans will be announced after the commercialization and ramp-up of these new products.
→No mention of debt or equity issuance was made during the call.
→The company maintains a strong cash balance of Rs. 400 crores despite increased CAPEX and higher dividend payout.
→The focus appears to be on internal cash generation and operational growth rather than immediate external fundraising.

Order book

The transcript does not explicitly state the current or expected order book or pending orders for Clean Science and Technology Limited. However, some relevant points that indirectly reflect demand and growth expectations include: - HALS sales volume grew significantly from 600 tons in FY '24 to approximately 2,000 tons in FY '25. - Target for HALS sales in FY '26 is 4,500 tons, with full capacity expansion planned by FY '28 (total capacity: 10,000 tons). - Successful validation by key customers in Middle East, Southeast Asia, and Europe indicates strong sales momentum. - The company expects revenue potential of Rs. 2,500 to Rs. 3,000 crores in the next three years. - Margins are expected to be maintained around 40% EBITDA on a consolidated basis. - CAPEX of Rs. 300 crores planned for current year to support new product commercializations. - Volume growth seen in existing products like MEHQ and BHA with capacity utilization around 70-72%, indicating scope for volume increase. No direct order book or pending orders data provided in the transcript.

Capex plans

Yes

→FY ’25 CAPEX: Rs. 215 crores invested in subsidiary Clean Fino-Chem.
→FY ’26 CAPEX: Rs. 300 crores planned, primarily for two new performance chemical projects.
→ - One product commercialization expected by August FY ’26.
→ - Second product commercialization expected by February FY ’26.
→Further CAPEX plans for FY ’27 will be announced around six months after these products come online.
→No immediate CAPEX projects slated for FY ’27 as of now; future investments contingent on commercialization progress.
→HALS capacity expansion (total capacity over 10,000 tons) ramp-up expected by FY ’28 before considering Phase-two expansion.

How does Clean Science & Technology Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Clean Science & Technology Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Clean Science & Technology Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio